Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma

May 18, 2007 updated by: Catholic University of the Sacred Heart

Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma

The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Twenty ocular hypertension and twenty early open angle glaucoma patients will be randomly divided into two groups: 1. placebo group [ocular hypertension, n = 10, early glaucoma (n=10)], taking an oral placebo in addition to standard beta-blocker treatment for ocular hypertension; 2. Treatment group [ocular hypertension, n = 10, early glaucoma (n=10)], taking Epigallocatechingallate oral treatment (200 mg/day) in addition to standard beta-blocker treatment for ocular hypertension. The patients will undergo standard clinical examination including automated Humphrey perimetry (30-2), pattern electroretinogram recording and measurement of retinal nerve fiber layer thickness by Optical Coherence Tomography (OCT stratus) at baseline, 3 and 6 months of treatment and follow-up. All patients will be again tested at 3 and 6 months after changing, in a cross-over design, placebo with drug assumption and vice versa.

Main outcome measure will be pattern electroretinogram amplitude. Secondary measures will be Humphrey perimetry mean deviation and corrected pattern standard deviation, and the thickness of optic nerve fibers measured by OCT.

Pattern Electroretinogram recordings.

Stimuli will be horizontal gratings of 1.6 cycles/degree spatial frequency, modulated in counterphase at 8.14 Hz and electronically generated on a high-resolution TV monitor (contrast: 70%; mean luminance: 80 cd/m2; field size: 31° [width] x 24° [height]). Subjects fixate at the center of the stimulating field with natural pupils, whose size will be measured, at a viewing distance of 57 cm. The subjects or patients will wear full refractive correction for the test distance. Signals will be recorded by a standard, flat-cup, 9 mm Ag/AgCl electrode taped on the skin of the lower eyelid. A similar electrode, placed over the eyelid of the contralateral, unstimulated eye, will be used as reference. Responses will be amplified (100, 000), bandpass filtered (1-30 Hz), sampled with a resolution of 12 bits and averaged (250 events) with automatic artifact rejection. Two replications will be obtained for each record to verify reproducibility. Peak-to-peak amplitude (in microV) of the Fourier analyzed response 2nd harmonic will be measured.

Retinal Nerve Fiber Thickness by OCT

All patients will undergo OCT imaging (software version 4.0.1, Carl Zeiss Meditec Ophthalmic Systems Inc, Dublin, CA) of the peripapillary RNFL. The instrument will be properly aligned after the subjects are comfortably seated with their head and chin firmly positioned against the relative rests. The OCT lens will be adjusted for the patient's refractive error. The subject will be instructed to stare at the internal fixation target with the eye under examination, to enable the optic disc to come into the window and to be successively centered. The Z-offset and the polarization will be adjusted to optimize the axial interval to the OCT scan and to maximize the reflective signal, respectively. The scan protocol will be the fast RNFL thickness 3.4 (3 circular scans consecutively performed, each 3.46 mm in diameter, centered on the optic disc and averaged to form a mean baseline). All scans will be acquired five times per eye during the same day, with short breaks between measurements, under dark room conditions. Images with eye movements during scans, poor centration, poor focus, or a signal strength less than 7/10 were excluded. The mean of 3 separate RNFL measurements (256 A-scans each) with the best optic disc centration, reproducibility of the signal profiles and signal strength will be used. Retinal thickness will be measured with the location of the vitreoretinal interface and the retinal pigment epithelium defining the inner and outer boundaries of the retina, respectively. The boundaries of the RNFL will be defined by first determining the thickness of the neurosensory retina. The location of the posterior boundary of the RNFL will be determined by evaluating each A-scan for a threshold chosen to be 15 dB greater than the filtered maximum reflectivity of the adjacent retina. Various machine-generated parameters will be used for evaluation of RNFL thickness, including RNFL average thickness over the entire cylindrical section and average RNFL thickness in each quadrant (inferior, superior, temporal and nasal). Abnormal RNFL measurements using OCT will be defined as mean or quadrantic thickness values outside 95% normal limits, based on the instrument's normative age-matched database, that will be confirmed on at least three out of five repeat scans. The reference values obtained from the normal control group included in the study will be also considered. The average RNFL thickness, inferior RNFL thickness, and the superior RNFL thickness have been shown to be the best discriminators for glaucoma by the Stratus OCT. These three measures will be the RNFL parameters analyzed in our study. One author (DM) will perform all the image acquisitions.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Rome, Italy, 00168
        • Recruiting
        • Catholic University, Policlinico A. Gemelli (Hospital)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • IOP > 21 mmHg at the time of diagnosis
  • Response to ipotensive therapy
  • No visible alterations of the optical nerve head (if OHT)
  • Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
  • Alterations in PERG
  • Familiarity for glaucoma (if OHT)

Exclusion Criteria:

  • Change of ipotensive therapy
  • Ocular surgery
  • Other ocular pathologies
  • Smokers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
PERG
Time Frame: six months
six months

Secondary Outcome Measures

Outcome Measure
Time Frame
IOP
Time Frame: six months
six months
Optical Coherence Tomography measurements of retinal nerve fiber layer thickness
Time Frame: six months
six months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Catholic University of the Sacred Heart

Investigators

  • Principal Investigator: Benedetto Falsini, MD, Chatolic University of Sacred Heart, Roma
  • Principal Investigator: Tommaso Salgarello, M.D., Catholic University, Italy
  • Principal Investigator: Dario Marangoni, M.D., Catholic University, Italy

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Study Completion (Anticipated)

July 1, 2008

Study Registration Dates

First Submitted

May 18, 2007

First Submitted That Met QC Criteria

May 18, 2007

First Posted (Estimate)

May 21, 2007

Study Record Updates

Last Update Posted (Estimate)

May 21, 2007

Last Update Submitted That Met QC Criteria

May 18, 2007

Last Verified

May 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FISIONERVE-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Open Angle Glaucoma

Clinical Trials on Epigallocatechin-gallate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe